Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption.

Autor:	Ribeiro ÁCDS; Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Diadema, SP, Brasil., Crozatti MTL; Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Diadema, SP, Brasil., Silva AAD; Universidade Presbiteriana Mackenzie, Centro de Ciências Sociais e Aplicadas, São Paulo, SP, Brasil., Macedo RS; Universidade Federal de São Paulo, Hospital Universitário da UNIFESP/Hospital São Paulo, São Paulo, SP, Brasil., Machado AMO; Universidade Federal de São Paulo. Departamento de Medicina. Laboratório Central do Hospital São Paulo, São Paulo, SP, Brasil., Silva ATA; Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Diadema, SP, Brasil.
Jazyk:	angličtina
Zdroj:	Revista da Sociedade Brasileira de Medicina Tropical [Rev Soc Bras Med Trop] 2019 Dec 20; Vol. 53, pp. e20180498. Date of Electronic Publication: 2019 Dec 20 (Print Publication: 2019).
DOI:	10.1590/0037-8682-0498-2018
Abstrakt:	Introduction: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance. Methods: Data were obtained from ICUs between 2010 and 2013. Results: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B. Conclusions: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu